Mesa Labs Details Executive Pay, Equity Awards in Latest Proxy Filing
Ticker: MLAB · Form: DEF 14A · Filed: Jul 11, 2025 · CIK: 724004
| Field | Detail |
|---|---|
| Company | Mesa Laboratories Inc /Co/ (MLAB) |
| Form Type | DEF 14A |
| Filed Date | Jul 11, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: Executive Compensation, Equity Awards, Proxy Statement, Corporate Governance, Industrial Instruments, DEF 14A, Shareholder Value
Related Tickers: MLAB
TL;DR
MLAB's proxy filing shows a heavy lean on equity awards for executive pay, so watch those vesting schedules closely; it's all about long-term alignment.
AI Summary
Mesa Laboratories Inc. (MLAB) filed its DEF 14A on July 11, 2025, outlining executive compensation and governance for the fiscal year ending March 31, 2025. The filing indicates a focus on equity awards and their valuation, with specific data points for 'Dividends or Other Earnings Paid on Equity Awards Not Otherwise Reflected in Total Compensation for Covered Year' and 'Fair Value as of Prior Year End of Equity Awards Granted in Prior Years Filed Vesting Conditions During Covered Year'. For the period 2023-04-01 to 2024-03-31, the company reported specific values for these equity awards for both 'Non-PEO NEO' and 'PEO' members, though exact dollar amounts are not explicitly detailed in the provided snippet. The strategic outlook appears to involve continued reliance on equity-based incentives for executive and non-executive compensation, aligning with long-term performance. Risks are primarily related to the valuation and vesting conditions of these equity awards, which can fluctuate with market conditions. The company operates in the industrial instruments sector, suggesting a stable but competitive market.
Why It Matters
This DEF 14A filing provides crucial transparency into Mesa Laboratories' executive compensation structure, particularly its reliance on equity awards. For investors, understanding how executives are incentivized directly impacts shareholder alignment and potential dilution from stock grants. Employees, especially those with equity, will watch vesting schedules and valuation changes closely. In the competitive industrial instruments sector, a well-structured compensation plan can attract and retain top talent, influencing the company's long-term innovation and market position. This filing helps stakeholders assess governance and management's commitment to performance.
Risk Assessment
Risk Level: medium — The risk level is medium due to the significant reliance on equity awards for compensation, as indicated by the detailed tracking of 'Dividends or Other Earnings Paid on Equity Awards' and 'Fair Value as of Prior Year End of Equity Awards Granted in Prior Years'. While equity aligns executive interests with shareholders, it introduces volatility based on stock performance and market conditions, which can impact executive retention and motivation if the stock underperforms. The filing doesn't detail specific performance metrics tied to these awards, making it harder to assess the rigor of the compensation plan.
Analyst Insight
Investors should scrutinize the full DEF 14A filing to understand the specific performance metrics tied to executive equity awards and their vesting schedules. Evaluate if the compensation structure adequately incentivizes long-term shareholder value creation and if potential dilution from these awards is acceptable given the company's growth prospects.
Key Numbers
- 2025-07-11 — Filing Date (Date the DEF 14A was filed)
- 2025-08-22 — Conformed Period of Report (Period covered by the report)
- 0000724004 — Central Index Key (CIK) (Unique identifier for Mesa Laboratories Inc.)
- 3823 — SIC Code (Industrial Instruments for Measurement, Display, and Control)
- 000-11740 — SEC File Number (Mesa Laboratories Inc.'s SEC file number)
- 1934 Act — SEC Act (Act under which the DEF 14A was filed)
Key Players & Entities
- MESA LABORATORIES INC /CO/ (company) — Filer of DEF 14A
- SEC (regulator) — Recipient of the DEF 14A filing
- Bloomberg (company) — Publisher of this analysis
- Non-PEO NEO (person) — Category of executive compensation recipients
- PEO (person) — Category of executive compensation recipients
- Colorado (company) — State of incorporation for Mesa Laboratories Inc.
- Lakewood (company) — City of Mesa Laboratories Inc.'s business address
FAQ
What is the primary purpose of Mesa Laboratories Inc.'s DEF 14A filing?
The primary purpose of Mesa Laboratories Inc.'s DEF 14A filing, submitted on July 11, 2025, is to provide shareholders with information regarding executive compensation, corporate governance, and proposals to be voted on at the upcoming annual meeting, specifically covering the fiscal year ending March 31, 2025.
How does Mesa Laboratories Inc. compensate its executives according to the filing?
According to the DEF 14A filing, Mesa Laboratories Inc. compensates its executives, including 'Non-PEO NEO' and 'PEO' members, significantly through equity awards. The filing details 'Dividends or Other Earnings Paid on Equity Awards' and 'Fair Value as of Prior Year End of Equity Awards Granted in Prior Years Filed Vesting Conditions During Covered Year' for periods like 2023-04-01 to 2024-03-31.
What fiscal period does this Mesa Laboratories Inc. DEF 14A cover?
This Mesa Laboratories Inc. DEF 14A filing, dated July 11, 2025, covers the fiscal period ending March 31, 2025, with specific data points provided for various periods leading up to this date, such as 2023-04-01 to 2024-03-31 for equity award valuations.
What are the potential risks associated with Mesa Laboratories Inc.'s compensation structure?
The potential risks associated with Mesa Laboratories Inc.'s compensation structure, particularly its reliance on equity awards, include volatility in executive compensation tied to stock performance and potential shareholder dilution. The filing indicates detailed tracking of equity award values, suggesting a significant portion of compensation is equity-based.
Where is Mesa Laboratories Inc. headquartered?
Mesa Laboratories Inc. is headquartered at 12100 W 6th Ave, Lakewood, Colorado 80228. This information is provided in the business address section of the DEF 14A filing.
What industry does Mesa Laboratories Inc. operate in?
Mesa Laboratories Inc. operates in the 'Industrial Instruments for Measurement, Display, and Control' industry, as indicated by its Standard Industrial Classification (SIC) code 3823 in the DEF 14A filing.
How can investors use the information in Mesa Laboratories Inc.'s DEF 14A?
Investors can use the information in Mesa Laboratories Inc.'s DEF 14A to evaluate the alignment of executive incentives with shareholder interests, assess potential dilution from equity awards, and understand the company's corporate governance practices. This helps in making informed investment decisions regarding MLAB stock.
What is the Central Index Key (CIK) for Mesa Laboratories Inc.?
The Central Index Key (CIK) for Mesa Laboratories Inc. is 0000724004, as stated in the DEF 14A filing. This unique identifier is used by the SEC to identify the company.
Has Mesa Laboratories Inc. changed its name historically?
Yes, Mesa Laboratories Inc. has changed its name historically. The filing indicates it was formerly known as MESA LABORATORIES INC /CO/ with a name change date of 19951117, and prior to that, MESA MEDICAL INC with a name change date of 19921123.
What is the significance of equity awards in Mesa Laboratories Inc.'s compensation?
Equity awards are highly significant in Mesa Laboratories Inc.'s compensation, as evidenced by the detailed reporting of 'Dividends or Other Earnings Paid on Equity Awards' and 'Fair Value as of Prior Year End of Equity Awards Granted in Prior Years Filed Vesting Conditions During Covered Year' for both 'Non-PEO NEO' and 'PEO' members across multiple fiscal years, suggesting a core component of executive remuneration.
Industry Context
Mesa Laboratories Inc. operates within the Industrial Instruments for Measurement, Display, and Control sector (SIC 3823). This industry is characterized by a need for precision, reliability, and compliance with various industry standards. Companies in this space often serve critical functions in manufacturing, healthcare, and environmental monitoring, facing competition from both specialized niche players and larger diversified industrial conglomerates.
Regulatory Implications
As a public company, Mesa Laboratories Inc. is subject to SEC regulations governing disclosures, particularly concerning executive compensation and corporate governance as outlined in the DEF 14A. Compliance with accounting standards for equity awards and accurate valuation reporting are critical to avoid regulatory scrutiny and maintain investor confidence.
What Investors Should Do
- Analyze equity award vesting schedules and performance metrics.
- Review the fair value changes of equity awards over time.
- Evaluate the 'Dividends or Other Earnings Paid on Equity Awards' component.
Key Dates
- 2025-07-11: DEF 14A Filing — Indicates the company has disclosed executive compensation and governance details for the relevant fiscal year.
- 2025-08-22: Conformed Period of Report — Defines the reporting period covered by the DEF 14A filing, which is crucial for understanding the context of the disclosed information.
- 2025-03-31: Fiscal Year End — Marks the end of the fiscal year for which the financial and compensation data in the DEF 14A is reported.
Glossary
- DEF 14A
- A proxy statement filed by public companies with the SEC detailing information about executive compensation, board of directors, and other corporate governance matters. (This filing provides the core data on executive compensation and governance for Mesa Laboratories Inc.)
- PEO NEO
- Principal Executive Officer (PEO) and Named Executive Officers (NEOs). These are the top executives of the company whose compensation is disclosed in detail. (The filing distinguishes compensation and equity award details between the PEO and other NEOs.)
- Non-PEO NEO
- Named Executive Officers (NEOs) who are not the Principal Executive Officer (PEO). (This category allows for a separate analysis of compensation for executives other than the CEO.)
- Equity Awards
- Awards granted to employees in the form of company stock, stock options, or other equity-based instruments. (The filing highlights the importance of equity awards in Mesa Laboratories' executive compensation strategy.)
- Vesting Conditions
- The criteria that must be met for an employee to gain full ownership of granted equity awards. (These conditions are critical for understanding the timing and realization of executive compensation from equity awards.)
- Fair Value as of Prior Year End of Equity Awards Granted in Prior Years Filed Vesting Conditions During Covered Year
- The market value of equity awards granted in previous years that met their vesting conditions during the current reporting year, as assessed at the end of the prior fiscal year. (This metric helps in understanding the value realization of long-term incentive plans.)
- Dividends or Other Earnings Paid on Equity Awards Not Otherwise Reflected in Total Compensation for Covered Year
- Any dividends or earnings distributed on unvested equity awards during the reporting period that are not already included in the total compensation calculation. (This provides a more complete picture of the economic benefits derived from equity awards.)
Year-Over-Year Comparison
This DEF 14A filing for the period ending March 31, 2025, provides updated details on executive compensation and governance compared to the previous year's filing. While specific comparative financial figures are not detailed in this excerpt, the emphasis on equity awards and their valuation metrics suggests a continued strategy of using stock-based incentives to align executive pay with company performance. Investors should compare the reported values for 'Dividends or Other Earnings Paid on Equity Awards' and 'Fair Value as of Prior Year End of Equity Awards' to assess any changes in executive compensation realization and the underlying stock performance.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on July 11, 2025 by Non-PEO NEO regarding MESA LABORATORIES INC /CO/ (MLAB).